NASDAQ: ACHL - Achilles Therapeutics plc

Yield per half year: +39.32%
Dividend yield: 0.00%
Sector: Healthcare

Company Analysis Achilles Therapeutics plc

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (21.57%) is higher than the sector average (-37.33%).

Disadvantages

  • Price (1.17 $) is higher than fair price (1.14 $)
  • Dividends (0%) are below the sector average (0.5399%).
  • Current debt level 2.86% has increased over 5 years from 0.4629%.
  • The company's current efficiency (ROE=-49.12%) is lower than the sector average (ROE=9.39%)

Similar companies

Alexion

Amgen

ABIOMED

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Achilles Therapeutics plc Healthcare Index
7 days 1.3% -1.7% -2.5%
90 days 16.7% -40.1% 2%
1 year 21.6% -37.3% 21.7%

ACHL vs Sector: Achilles Therapeutics plc has outperformed the "Healthcare" sector by 58.89% over the past year.

ACHL vs Market: Achilles Therapeutics plc has underperformed the market marginally by -0.0848% over the past year.

Stable price: ACHL is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: ACHL with weekly volatility of 0.4147% over the past year.

3. Summary of the report

3.1. General

P/E: 0.47
P/S: 0

3.2. Revenue

EPS -1.75
ROE -49.12%
ROA -43.32%
ROIC -27.35%
Ebitda margin 0%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (1.17 $) is higher than the fair price (1.14 $).

Price is higher than fair: The current price (1.17 $) is 2.6% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (0.47) is lower than that of the sector as a whole (61.47).

P/E vs Market: The company's P/E (0.47) is lower than that of the market as a whole (51.48).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (0.2323) is lower than that of the sector as a whole (4.79).

P/BV vs Market: The company's P/BV (0.2323) is lower than that of the market as a whole (3.44).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (33.58).

P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.3).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (1.17) is higher than that of the sector as a whole (-17.26).

EV/Ebitda vs Market: The company's EV/Ebitda (1.17) is lower than that of the market as a whole (29.6).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 22.38% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (22.38%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).

5.4. ROE

ROE vs Sector: The company's ROE (-49.12%) is lower than that of the sector as a whole (9.39%).

ROE vs Market: The company's ROE (-49.12%) is lower than that of the market as a whole (8.95%).

5.5. ROA

ROA vs Sector: The company's ROA (-43.32%) is lower than that of the sector as a whole (0.1519%).

ROA vs Market: The company's ROA (-43.32%) is lower than that of the market as a whole (6.3%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-27.35%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-27.35%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (2.86%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 0.4629% to 2.86%.

Excess of debt: The debt is not covered by net income, percentage -6.6%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Achilles Therapeutics plc

9.3. Comments